^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Neuroendocrine Tumor |
| Drug: | Loqtorzi (toripalimab-tpzi) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Study of JS001 in Patients With Advanced Neuroendocrine Tumors
Excerpt:
...Providing with tumor specimen (for testing the expression of PD L1 and the infiltrating lymphocytes); 10....
Trial ID:
Source:
Title:
Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial
Published date:
02/21/2020
Excerpt:
The median DOR was 15.2 months. Patients with PD-L1 expression (≥10%) or high tumor mutational burden (TMB) had better ORR than PD-L1 <10% (50.0% vs. 10.7%, P = 0.019) and TMB-low patients (75.0% vs. 16.1%, P = 0.03). Three of 8 (37.5%) responders harbored ARID1A mutations...Toripalimab had antitumor activity and safety in treating recurrent or metastatic NENs...Patients with positive PD-L1 expression, TMB-H (top 10%), and/or microsatellite instable (MSI-H) might preferentially benefit from the treatment.
DOI:
10.1158/1078-0432.CCR-19-4000
Trial ID:
